or eye problems caused by diabetes (retinopathy)
[3] Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus, but was discontinued due to lack of efficacy
It combines antioxidant protection, detoxification, and skin lightening benefits, making it a popular choice for those seeking a non-invasive method to improve their appearance
93-105 Coplan JD et al (2021) Early life stress and the fate of kynurenine pathway metabolites
Erabi H, Okada G, Shibasaki C, Setoyama D, Kang D, Takamura M, et al
Seven additional Phase 3 trials from the TRIUMPH program are expected to report results throughout 2026, including trials in type 2 diabetes, obstructive sleep apnea, and general obesity without specific comorbidities